Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : India Coffee House -- Ignore unavailable to you. Want to Upgrade?

To: Mohan Marette who wrote (4810)	6/30/1999 1:10:00 PM
From: Mohan Marette	Respond to of 12475

Ranbaxy gets FDA approval for anti-infective drug ranbaxy.com NEW DELHI, June 30 (Reuters) - Ranbaxy Pharmaceuticals Inc, a subsidiary of India's Ranbaxy Laboratories , said on Wednesday it had won U.S. Food and Drug Administration (FDA) approval to market an anti-infective drug in the United States. The company said in a statement that it got FDA approval to market Cefadroxil Hemihydrate drug as one gram tablets and another company, Barr Laboratories, also got FDA approval to market the drug as 500 gram capsules. The two companies plan to co-market the drug. ''Plans are in place to co-market each dosage form of this product under each company's respective labels immediately,'' Ranbaxy said. The company said it will start shipment of the drug from July. biz.yahoo.com